Scott Dreyer: Yes, thanks. So, to your first question, Les, when it comes to the levers that mitigate the erosion. The primary lever we have is look where those were lost were almost all commercial plans and so we have a co-pay program that offsets the cost to the patient, and that’s a big lever for us in addition to our overall commercialization effort and push through with physicians across all our marketing and sales activities. In terms of the patients and kind of patient flows, what we see across the portfolio are the brands are each uniquely positioned in the minds of the physician and have a unique space, but by all means if someone fails on Xtampza, we will sometimes see a move to Belbuca and vice versa.
Joe Ciaffoni: Okay. And then Les, with regards to part the opportunity with all Part D plans really sets up for the first quarter of 2024. That’s when the renewals take place which are 12 months. It’s about 60% of them occur in that time period. So that’s what we’re focused on and targeting.
Les Sulewski: That’s helpful. One more from me on the BD front. What’s your funnel essentially look like now. Are there any opportunities essentially in other non-abuse-deterrent options available in the market now, and then, if not other opportunities out there and what does the competitive landscape essentially look like and also valuations in the current market environment. Thank you.
Joe Ciaffoni: Thanks for the question. So look therapeutically and we’ve talked about this in the past with the current market conditions, we’re going to be very agile, I wouldn’t say we’re therapeutically agnostic. But we’re open to anything that really hits the profile of a differentiated commercial stage asset with $150 million plus peak sales potential with exclusivity into the 2030s. Whatever acquisition, we’re able to achieve, we will not be like the ones we’ve done in the past where we’re leveraging our PAIN infrastructure, we’ll be setting a second commercial beachhead. So these will be a lower synergy, more strategically oriented deal for Collegium and that’s our focus. In terms of valuations, what I would say, Les, is right now, what we’ve seen is a lot of receptivity in willingness to engage.
And whilst the financial strength of our company and the fact that we don’t have to do a deal, we aspire to do one will continue to engage and work with urgency. But we won’t strike until we get to a price that we’re comfortable with and believe creates value for our shareholders.
Operator: Thank you. There are no further questions at this time. I would now like to turn the floor back over to Joe for closing comments.
Joe Ciaffoni: Thank you, operator and thank you everyone for joining the call. We look forward to updating you on our progress and we hope everyone has a great evening.
Operator: This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.
